<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991116</url>
  </required_header>
  <id_info>
    <org_study_id>TILD-21-01</org_study_id>
    <nct_id>NCT04991116</nct_id>
  </id_info>
  <brief_title>Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis</brief_title>
  <official_title>An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label phase 3 study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects from both INSPIRE 1 (TILD-19-07) and INSPIRE 2 (TILD-19-19) studies to roll over&#xD;
      into this INSPIRE LTE study (TILD-21-01).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and intensity of Adverse Events (AEs) recorded through the study period</measure>
    <time_frame>Week 124</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20</measure>
    <time_frame>Week 124</time_frame>
    <description>ACR20 response is an aggregate of:&#xD;
1. at least 20% reduction in tender joint count and swollen joint count and at least 3 of the following 5 assessments:&#xD;
physician's global assessment of disease activity&#xD;
patient's global assessment of disease activity&#xD;
patient's assessment of pain&#xD;
patient's self-assessed disability based on health assessment questionnaire&#xD;
c-reactive protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects Who Reached (American College of Rheumatology Score of 50) ACR50</measure>
    <time_frame>Week 124</time_frame>
    <description>ACR50 response is an aggregate of:&#xD;
1. at least 50% reduction in tender joint count and swollen joint count and at least 3 of the following 5 assessments:&#xD;
physician's global assessment of disease activity&#xD;
patient's global assessment of disease activity&#xD;
patient's assessment of pain&#xD;
patient's self-assessed disability based on health assessment questionnaire&#xD;
c-reactive protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects Who Reached (American College of Rheumatology Score of 70) ACR70</measure>
    <time_frame>Week 124</time_frame>
    <description>ACR70 response is an aggregate of:&#xD;
1. at least 70% reduction in tender joint count and swollen joint count and at least 3 of the following 5 assessments:&#xD;
physician's global assessment of disease activity&#xD;
patient's global assessment of disease activity&#xD;
patient's assessment of pain&#xD;
patient's self-assessed disability based on health assessment questionnaire&#xD;
c-reactive protein</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>TILD q12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TILD sub-cutaneous (SC) injection</intervention_name>
    <description>1 mL injection of study medication</description>
    <arm_group_label>TILD q12 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects possess the ability to understand the requirements of the study.&#xD;
&#xD;
          -  Subject has provided written informed consent as evidenced by signature on an informed&#xD;
             consent form approved by an institutional review board/EC.&#xD;
&#xD;
          -  Agree to abide by the study restrictions, scheduled treatment, laboratory assessments,&#xD;
             other study procedures and return to the site for the required assessments.&#xD;
&#xD;
          -  Subject with PsA who had met all eligibility criteria for the parent study, had&#xD;
             completed the parent study treatment period and has not developed any parent protocol&#xD;
             criteria for premature discontinuation of treatment or withdrawal from the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects of childbearing potential who do not agree to abstain from&#xD;
             heterosexual activity or practice a dual method of contraception.&#xD;
&#xD;
          -  Female is pregnant or breastfeeding, or planning to become pregnant or initiate&#xD;
             breastfeeding while enrolled in the study or up to 17 weeks after the last dose of&#xD;
             IMP.&#xD;
&#xD;
          -  Subject has previously been enrolled in this long-term extension study.&#xD;
&#xD;
          -  Any condition that in the opinion of the Investigator represents an obstacle for study&#xD;
             conduct and/or represents a potential unacceptable risk for the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head, Clinical Developement</last_name>
    <phone>9122 66455645</phone>
    <email>clinical.trials@sparcmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunpharma site no. 30</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Samy Metyas, M.D..</last_name>
      <phone>626-860-5730</phone>
      <email>drmetyas@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 17</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Vivian T Laquer, M.D</last_name>
      <phone>714-531-2966</phone>
      <email>vivian.laquer@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 15</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91320</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Navid Ezra, M.D.</last_name>
      <phone>805-222-5803</phone>
      <email>navid.ezra@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 21</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Levin, M.D.</last_name>
      <phone>727-734-6631</phone>
      <email>rlevin@crwf.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 02</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Carlos A Sesin, M.D.</last_name>
      <phone>305-456-9062</phone>
      <email>c.sesin@sweethoperesearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 19</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ricardo J Garcia-Alemany, M.D.</last_name>
      <phone>305-631-6704</phone>
      <email>rgarciamd@suncoastresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 05</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34668</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Farrukh Zaidi, M.D.</last_name>
      <phone>727-849-4131</phone>
      <email>fzaidi@suncoastclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SunPharma Site no 22</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Steven Kimmel, M.D.</last_name>
      <phone>954-545-8400</phone>
      <email>wbrakimmel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 29</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jefrey Lieberman, M.D.</last_name>
      <phone>770-667-0220</phone>
      <email>jlieberman@csiresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 20</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shadi H Shahouri, M.D., FACR</last_name>
      <phone>316-689-6683</phone>
      <email>shadi.shahouri@amrllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma Site no 26</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70605</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Enrique Mendez, M.D.</last_name>
      <phone>337-312-8619</phone>
      <email>emendezmd@accurateclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 07</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Charles A Birbara, M.D.</last_name>
      <phone>508-755-0201</phone>
      <email>cabirbara@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 10</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joshua P June, D.O.</last_name>
      <phone>517-272-9727</phone>
      <email>joshua.june@glcor.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 14</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David G True, D.O., FACR</last_name>
      <phone>417-883-7889</phone>
      <email>dtrue@clinvest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma Site no 27</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Melvin Churchill, M.D.</last_name>
      <phone>402-420-3433</phone>
      <email>Melvin.Churchill@nebraskaarthritis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 09</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>John H Tu, M.D., M.S</last_name>
      <phone>585-697-1818</phone>
      <email>jtresearch@dermrochester.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 18</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael E Luggen, M.D.</last_name>
      <phone>513-559-2370</phone>
      <email>mluggen@crdsg.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 11</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Isam A Diab, M.D.</last_name>
      <phone>440-826-0742</phone>
      <email>IDIABMD@GMAIL.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 25</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Borofsky, M.D.</last_name>
      <phone>610-375-2466</phone>
      <email>mborofsky@crcreading.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no 31</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeff Lawson, M.D.</last_name>
      <phone>864-527-2307</phone>
      <email>lawson@piedmontarthritis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 13</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sabeen Najam, M.D.</last_name>
      <phone>281-422-7179</phone>
      <email>snajammd@accurateclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 06</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephen K Tyring, M.D., Ph. D., M.B.A</last_name>
      <phone>281-333-2288</phone>
      <email>styring@ccstexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 08</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amber Khan, M.D.</last_name>
      <phone>832-672-7973</phone>
      <email>akhanmd@accurateclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 04</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Prashanth R Sunkureddi</last_name>
      <phone>713-677-0086</phone>
      <email>psunkureddimd@accurateclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma Site no 28</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jitendra Vasandani, M.D.</last_name>
      <phone>806-993-1040</phone>
      <email>jitendra.vasandani@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 03</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alex De Jesus, M.D., P.A.</last_name>
      <phone>210-980-1742</phone>
      <email>adejesusmd@accurateclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 16</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Pendleton B Wickersham, M.D.</last_name>
      <phone>210-477-2626</phone>
      <email>drwickersham@cttexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 01</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Arif Ali Shaikh, M.D.</last_name>
      <phone>281-517-0550</phone>
      <email>drali@dmclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 12</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric C Mueller, M.D.</last_name>
      <phone>509-838-6500</phone>
      <email>muellerresearch@arthritisnw.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpharma site no. 24</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Jane Zochling, Mmed, FRACP</last_name>
      <phone>61-36223-8802</phone>
      <email>jzochling@southernclinicalresearch.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SunPharma Site No 23</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Alejandro Escudero Contreras, Degree in Med.</last_name>
      <phone>34957010429</phone>
      <email>alejandro.escudero.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

